We and others have recently demonstrated that miR-26a possessed the tumor-suppressive functions by directly targeting the EZH2 oncogene in cancers e.g. nasopharyngeal carcinoma [30], lymphoma [60] and HBV-associated HCC cells (Figure S3). Here, EZH2 is linked to hepatocellular carcinoma.